Bristol-Myers to buy Celgene in $74 billion cancer-drug bet
Bloomberg Bristol-Myers Squibb agreed to acquire Celgene Corp in a record-sized $74 billion deal that will unite two drugmakers battling for advantage in a crowded market for innovative cancer treatments. Both companies have faced investor wariness about their prospects in recent months. Bristol makes an immunotherapy drug called Opdivo that accounts for roughly a quarter of its sales but that ...
Read More »